In the context of clinical trial data and personal experience, experts weigh the value of circulating tumor DNA as a tool in cancer care.

Experts share their perspective on clinical trial data driving the use of circulating tumor DNA in various settings of cancer care.

Experts indicated that 77% of women with lung cancer who were surveyed reported having moderate to severe sexual dysfunction.

The phase 3 RATIONALE 301 trial examining first-line tislelizumab vs sorafenib in unresectable hepatocellular carcinoma met the primary end point of noninferior overall survival.

Patients with advanced PD-L1–positive non–small cell lung cancer and squamous histology who were treated with sitravatinib plus tiselizumab had promising antitumor activity.

Paul G. Richardson, MD, looks at MRD data from the DETERMINATION study for its potential to guide treatment selection in newly diagnosed multiple myeloma.

Juan Pablo Alderuccio, MD, spoke with CancerNetwork® about a review article on the treatment of marginal zone lymphoma published in the journal ONCOLOGY®.

TROPION-Lung02 trial provides evidence of datopotamab deruxtecan and pembrolizumab efficacy in patients with advanced/metastatic non–small cell lung cancer and no actionable genomic alterations.

Overall survival, the primary end point of the phase 3 FRESCO-2 trial, was met when patients were given fruquintinib vs placebo for advanced refractory metastatic colorectal cancer.

Durvalumab plus tremelimumab in the first-line setting yielded improved overall survival vs chemotherapy in patients with metastatic non–small cell lung cancer.